Avexa Of Australia Reports Good Results With HIV Drug
This article was originally published in PharmAsia News
Executive Summary
Australian drug maker Avexa reports positive results from a Phase II study of its apricitabine HIV drug to treat patients unresponsive to GlaxoSmithKline's Epivir (lamivudine). Avexa CEO Julian Chick said the study showed the firm's drug to be at least as good as the safest HIV drug on the market. The study reported the drug reduced the AIDS-causing virus to insignificant levels in 89 percent of patients. Avexa seeks to license marketing rights to a larger partner so it can complete the studies this year. (Click here for more